Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has signed a nonexclusive
licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic
hepatitis C medicines. The medicines include sofosbuvir, ledipasvir/sofosbuvir and the investigational NS5A
inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that
combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C.
This agreement allows Natco to expand access to these chronic hepatitis C medicines in 91 developing
countries. Under the license, Natco can set its own price for the generic products it produces, paying a
royalty on sales to Gilead to support product registrations, medical education and training, safety
monitoring and other essential business activities.